A randomised double-blind placebo-controlled trial of bevacizumab anti-VEGF antibody demonstrating a prolongation time to progression in patients with metastatic renal cancer - Yang, JC; Haworth, L; Steinberg, SM (Proc Am Soc Clin Oncol, 2002)
et al.